ライフサイエンスコーパス: multikinase

1 so known as Arg82 and inositol polyphosphate multikinase).

2 ARG82, which encodes inositol polyphosphate multikinase.

3 r Ipk2 (also known as inositol polyphosphate multikinase), an inositol trisphosphate and tetrakisphos

4 uble forms, the human inositol polyphosphate multikinase, and the two isoforms of IP(3)K found in Dro

5 oups, inositol 3-kinases, inositol phosphate multikinases, and inositol hexakisphosphate kinases.

6 Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression

7 hosphate 3-kinase and inositol polyphosphate multikinase as key mediators in the production of IP(5).

8 How Nef assembles the multikinase cascade to trigger the MHC-I down-regulation

9 e to the paranuclear region and assemble the multikinase cascade.

10 us cell cancer (HNSCC) cells to ponatinib, a multikinase FGFR-active inhibitor.

11 Human inositol phosphate multikinase (HsIPMK) critically contributes to intracell

12 or had been treated previously with a VEGFR multikinase inhibitor (cohort 2).

13 FR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity again

14 Sorafenib, a multikinase inhibitor approved for the treatment of adva

15 Sorafenib, a multikinase inhibitor approved for the treatment of RCC,

16 otocols to monitor responses to sorafenib, a multikinase inhibitor approved for treatment of renal ce

17 These mutations were sensitive to the multikinase inhibitor dasatinib, which antagonizes TNK2

18 previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3

19 The multikinase inhibitor META060 has been shown to inhibit

20 The multikinase inhibitor midostaurin inhibits KIT D816V, a

21 GSK1363089 (foretinib), a multikinase inhibitor of AXL, MET, and vascular endothel

22 Sorafenib, a multikinase inhibitor of cell proliferation and angiogen

23 tudy assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal

24 ational phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients.

25 down of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduced.

26 ition is a novel mechanistic explanation for multikinase inhibitor resistance in glioma cells.

27 The effects of the multikinase inhibitor sorafenib (BAY 43-9006), an agent

28 The multikinase inhibitor sorafenib (Nexavar, Bayer), used i

29 ve drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib (SFB) usually fails to e

30 We examined the interaction between the multikinase inhibitor sorafenib and histone deacetylase

31 We examined whether the multikinase inhibitor sorafenib and histone deacetylase

32 Interactions between the multikinase inhibitor sorafenib and the BH3-mimetic obat

33 Interactions between the multikinase inhibitor sorafenib and tumor necrosis facto

34 te stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in pat

35 We previously demonstrated that the multikinase inhibitor sorafenib induces apoptosis in mel

36 Only the multikinase inhibitor sorafenib is available for the man

37 advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic tre

38 In addition, the multikinase inhibitor sorafenib significantly reduces FB

39 The multikinase inhibitor sorafenib yielded similar effects

40 r rapamycin alone or in combination with the multikinase inhibitor sorafenib, all xenografts responde

41 antly, we found that the clinically valuable multikinase inhibitor sorafenib, and a natural alkaloid,

42 the kinase most efficiently inhibited by the multikinase inhibitor sorafenib, which has shown activit

43 patient before and during treatment with the multikinase inhibitor sorafenib.

44 zed with diverse drug classes, including the multikinase inhibitor sorafenib.

45 on increased the therapeutic efficacy of the multikinase inhibitor sorafenib.

46 Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR

47 he safety and efficacy of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, an

48 Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and

49 Sorafenib, a multikinase inhibitor targeting Ret and VEGFR, showed an

50 effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculatur

51 Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had

52 n U.S. Food and Drug Administration-approved multikinase inhibitor that also targets Src family, dram

53 Sorafenib is a multikinase inhibitor that induces apoptosis in human le

54 Sorafenib (Nexavar) is a broad-spectrum multikinase inhibitor that proves effective in treating

55 sistance could be overcome with ponatinib, a multikinase inhibitor that targets BCR-ABL and FGF recep

56 This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and recept

57 BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor c

58 Sorafenib is an oral multikinase inhibitor that targets the Ras/Raf/MEK/ERK m

59 neoplastic drug sorafenib (BAY 43-9006) is a multikinase inhibitor that targets the serine-threonine

60 Sorafenib is an oral multikinase inhibitor that was originally developed as a

61 Sorafenib is an oral, multikinase inhibitor that was recently approved for use

62 Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase a

63 Cabozantinib is a multikinase inhibitor with activity against RET that pro

64 Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferat

65 Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activit

66 vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity ag

67 ffects of merestinib, an orally bioavailable multikinase inhibitor with suppressive effects on Mnk ac

68 Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat

69 ION: Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastat

70 Indeed, sorafenib (a multikinase inhibitor) is currently being used in the su

71 The discovery of sorafenib, a multikinase inhibitor, as a treatment with survival bene

72 Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in

73 Our aim was to ascertain if sorafenib, a multikinase inhibitor, may also inhibit JAK/STAT signali

74 Recently a multikinase inhibitor, sorafenib, has shown survival ben

75 h sunitinib (Sutent), an additional approved multikinase inhibitor, suggesting that the primary targe

76 ere sensitive to treatment with sorafenib, a multikinase inhibitor, that is used for HCC treatment.

77 hase I trial combining dasatinib, an SFK and multikinase inhibitor, with erlotinib, an EGFR inhibitor

78 oparticle containing cabozantinib (XL184)--a multikinase inhibitor--encapsulated inside.

79 ive iodine who had never been treated with a multikinase inhibitor.

80 ors were also resistant to a VEGFR targeting multikinase inhibitor.

81 The use of multikinase inhibitors (MKI) in oncology, such as sorafe

82 hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and ot

83 xis in normoxia and hypoxia and suggest that multikinase inhibitors may exert antiangiogenic effects

84 The Kit-targeting multikinase inhibitors PKC412 and dasatinib were also fo

85 ies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated

86 rapy against mCRPC-infiltrating MDSCs, using multikinase inhibitors such as cabozantinib and BEZ235,

87 The multikinase inhibitors sunitinib, sorafenib, and axitini

88 Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial gr

89 Several new targeted therapies with multikinase inhibitors targeting vascular endothelial gr

90 olypharmacological approaches for developing multikinase inhibitors with low toxicity profiles.

91 drives resistance of glioma cells to various multikinase inhibitors.

92 ctivity associated with several FDA-approved multikinase inhibitors.

93 peutic strategy of improving the efficacy of multikinase inhibitors.

94 nhibitors (TKIs) have significant off-target multikinase inhibitory effects.

95 al structure of the yeast inositol phosphate multikinase Ipk2 in the apoform and in a complex with AD

96 phosphate kinase 2 (Ipk2), also known as IP multikinase IPMK, is an evolutionarily conserved protein

97 We demonstrate that inositol polyphosphate multikinase (IPMK) acts noncatalytically as a transcript

98 RATIONALE: Inositol polyphosphate multikinase (IPMK) and its major product inositol pentak

99 es phosphorylation by inositol polyphosphate multikinase (IPMK) and promotes nuclear actin assembly t

100 Inositol-polyphosphate multikinase (IPMK) is a central component of the inosito

101 We show that inositol polyphosphate multikinase (IPMK) physiologically generates PIP(3) as w

102 We report that inositol polyphosphate multikinase (IPMK) regulates glucose signaling to AMPK i

103 ma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-media

104 repair, controlled by inositol polyphosphate multikinase (IPMK), an enzyme catalyzing inositol polyph

105 deletion in the gene inositol polyphosphate multikinase (IPMK), which truncates the protein.

106 Inositol phosphate multikinase (IPMK, also called Ipk2 and Arg82) accounts

107 human homolog of the rat inositol phosphate multikinase is an inositol 1,3,4,6-tetrakisphosphate 5-k

108 ently reported phase 2 study, midostaurin, a multikinase/KIT inhibitor, demonstrated an overall respo

109 ch we designate mammalian inositol phosphate multikinase (mIPMK).

110 provide evidence in vivo and in vitro for a multikinase pathway that links extracellular signals to

111 /FU positive regulatory loop nested within a multikinase phosphorylation cascade.

112 kinase assay to determine the mechanisms of multikinase substrate phosphorylation such as priming-de

113 n Trypanosoma brucei: inositol polyphosphate multikinase (TbIPMK), inositol pentakisphosphate 2-kinas

114 Inositol polyphosphate multikinase was identified as an enzyme that generates a

115 3-kinase activity of inositol polyphosphate multikinase, which is localized to nuclei and unaffected